EUCTR2015-003749-24-FR进行中（未招募）1 期
Effects of MagneB6® (470.0 mg Magnesium Lactate Dihydrate + 5.0 mg Pyridoxine Hydrochloride, Coated Tablet) Supplementation (8 Weeks) on Stress Levels of Chronically Stressed Subjects, with Suboptimal Serum Magnesium Levels- A Randomized, Single-blind Active Comparator, Multicentric Clinical Trial - Comparison with Magnespasmyl® (465.4 mg Magnesium Lactate Dihydrate, Coated Tablet) - MB6 SUPERIORITY
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female subjects aged between 18 and 50 years, chronically stressed (screening DASS-42 scale for chronic stress >18).
- •-Signed written informed consent.
- •-Moderate hypomagnesemic and low serum magnesium level subjects (0.5mmol/L -Women must use an effective contraceptive method during the study period.
- •-Body mass index (BMI) >18.5 and =29.9 kg/m^2.
- •-Able to understand the study, including risks and adverse events; collaborating with Investigator and proceeding according with protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 264
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Any technical/administrative reason (eg, subject homeless) that makes it impossible to randomize the patient in the study.
- •-Subject who has previously participated in any clinical trial of Magne B6 or Magnespasmyl.
- •-Subject who has taken other investigational drugs or prohibited therapy for this study within 3 months from screening.
- •-Conditions/situations such as:
- •-Subjects with conditions/concomitant diseases making them non evaluable for the primary endpoint.
- •-Requirement for concomitant treatment that could bias primary endpoint.
- •-Impossibility to meet specific protocol requirements (eg, for hospitalization).
- •-Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- •-Subject not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions or subjects potentially at risk of noncompliance to study procedures.
- •-Subjects with severe hypomagnesemia (serum magnesium less than or equal to 0.45 mmol/L).
- •-Subjects with moderate and severe kidney failure.
- •-Subjects treated with Levodopa.
- •-Subjects treated with quinidine.
- •-Any known allergies to the test substances, or with fructose intolerance, glucose and galactose malabsorption syndrome or sucrase-isomaltase deficiency due to sucrose content (excipient).
- •-Any known addiction to drugs and alcohol.
- •-Alcohol intake of at least 3 drinks/day.
- •-Type 1 or 2 diabetes mellitus.
- •-Active neoplasms.
- •-Known hyperthyroidism unless treated and under control.
- •-History of hepatic, renal, pulmonary, gastrointestinal, neurologic, hematologic, psychiatric, cardiac, or allergic disease clinically relevant.
- •-Laboratory results out of the normal range. In this case, subject can be included if the alterations are considered by the doctor as not relevant.
- •-The subject has an excessive tobacco consumption (smokes more than 10 cigarettes/day).
- •-Have used regular medication for 2 weeks before the study, except contraceptive oral method for women.
- •-Hospitalization up to 8 weeks before the study start.
- •-Treatment within 3 months before the study starts with a drug considered toxic.
- •-Treatment with proton-pump inhibitors (eg, omeprazole, pantoprazole, esomeprazole, lansoprazole/dexlansoprazole, rabeprazole/dexrabeprazole)
- •-Subject which has donate or lost 450 mL or more of blood within 3 months before the study.
- •-Maintaining therapy with any drug, except contraceptive oral pills.
- •-All contraindications of the Magnespasmyl or waning/precaution of use as displayed in the respective National Product Labeling that was used for defining these exclusion criteria. Any update of contraindications in labeling document (Magnespasmyl) occuring during the course of the study that should be considered systematically as a new exclusion criterion.
- •-Pregnant, lactating, or females planning pregnancy in the next year or women with noneffective contraceptive method during the study period.
- •-Subject who has withdrawn consent before enrollment/randomization.
- •-Despite screening of the subject, enrollment/randomization is stopped at the study level.
研究者
相似试验
招募中
2 期
Comparison of the effect of magnesium and vitamin B6 on the improvement of restless leg syndromeRestless legs syndrome.Restless legs syndromeIRCT2017070134806N1Arak University of Medical Sciences72
招募中
2 期
Evaluation of the effect of vitamin B6 on blood cells count in patients using linezolidIRCT20150721023282N13Esfahan University of Medical Sciences70
已完成
3 期
The effect of vitamin B6 in bipolar patientsBIPOLAR DISORDER.Bipolar mood disorderIRCT20200317046801N1Tehran University of Medical Sciences50
招募中
3 期
Effect of Vitamin B6 and L-acetyl-carnitin in Treatment of Carpal Tunnel SyndromeIRCT20210915052494N1Shiraz University of Medical Sciences60
Unknown
2 期
Vitamin B6 and Magnesium- A Clinical Trial on ASD PatientsAutism Spectrum DisorderNCT03963479Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh50